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Technological improvements in unbiased screening have accelerated drug target 
discovery. In particular, membrane-embedded and secreted proteins have gained 
attention because of their ability to orchestrate intercellular communication. 
Dysregulation of their extracellular protein–protein interactions (ePPIs) underlies 
the initiation and progression of many human diseases. Practically, ePPIs are also 
accessible for modulation by therapeutics since they operate outside of the plasma 
membrane. Therefore, it is unsurprising that while these proteins make up about 
30% of human genes, they encompass the majority of drug targets approved by 
the FDA. Even so, most secreted and membrane proteins remain uncharacterized 
in terms of binding partners and cellular functions. To address this, a number of 
approaches have been developed to overcome challenges associated with membrane 
protein biology and ePPI discovery. This chapter will cover recent advances that 
use high-throughput methods to move towards the generation of a comprehensive 
network of ePPIs in humans for future targeted drug discovery.
Keywords: drug discovery, high-throughput screening, extracellular protein–protein 
interactions, unbiased target discovery, receptors, membrane proteins, secreted 
proteins
1. Introduction: targeting ePPIs to address disease burden
The World Health Organization estimates that over 70% of deaths in 2016 
worldwide were due to non-communicable diseases like cardiovascular disease 
(CVD) and cancer. This number is expected to grow to over 80% by 2060 [1]. 
Even if these diseases arise from environmental damage, the disease states usually 
depend on altered cellular communication, driven at the molecular level by altered 
ePPIs. For example, interactions between immune cells and arterial walls through 
adhesion proteins can initiate positive feedback loops which drive atherosclerotic 
plaque formation in CVD [2]. Similarly, while genetic mutations are the root cause 
of cancer, aberrant cell–cell interactions allow cancer cells to evade the immune 
system [3], migrate [4], siphon nutrients [5] and ignore signals to stop growing 
[6]. EPPIs also contribute to communicable diseases, which, highlighted by the 
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(ongoing as of this writing) COVID-19 pandemic, can rapidly increase human 
deaths with the introduction of a novel pathogen. As with many pathogens, the 
virus underlying the pandemic, SARS-CoV-2, exploits host cell-surface receptors to 
enter cells to replicate and spread [7, 8].
Because ePPIs are often central to the initiation and progression of diseases, they 
offer opportunities for molecular intervention using drugs. Greater understanding 
of the ePPIs underlying diseases allows them to be effectively targeted and manipu-
lated to reverse disease phenotypes. For example, for CVD, several efforts to target 
different cytokines are showing promise in stemming the progression of athero-
sclerosis [9]. The development of cancer immunotherapies in the last decade has 
revolutionized cancer treatment. These treatments block ePPIs between immune 
checkpoint proteins such as CTLA-4 or PD-L1 and their binding partners to rein-
vigorate the body’s defenses [10]. Even with SARS-CoV-2, an antibody cocktail 
(REGN-COV2) that blocks the ePPI between the virus spike protein and receptors 
on the cell, has been shown to stop viral entry and has gained emergency authoriza-
tion for use in COVID-19 patients [11]. These examples highlight that identifying 
and targeting ePPIs can have strong therapeutic benefits in a variety of known and 
emerging diseases that make up a significant portion of human disease burden 
worldwide (Figure 1).
Despite the importance of ePPIs for both understanding and treating disease, 
our understanding of this field remains limited, especially compared to other 
classes of protein–protein interactions (PPIs). A main reason for this disparity is 
that common techniques for general PPI discovery are not well suited for ePPIs. 
Interactions between individual secreted or membrane proteins are typically weak, 
making them difficult to capture. Membrane proteins are biochemically recalcitrant 
and tend to misfold or aggregate outside of a native membrane context making 
them incompatible with many readouts designed for soluble proteins. Extracellular 
proteins also pick up many complex and heterogeneous post-translational modifica-
tions on their journey out of the cell, including specific disulfide bonds designed for 
the non-reducing extracellular environment. Since these can play roles in ePPIs but 
are not well characterized, they can be missed by common non-native expression 
Figure 1. 
Examples of therapeutically relevant ePPIs. (A) The tumor microenvironment consists of a complex mix 
of cell types that communicate through ePPIs. One example is the expression of immune checkpoint proteins 
such as PD-L1 on cancer cells, which inhibits cytotoxic T-cell function, allowing the cancer cells to evade the 
immune system. Drugs targeting these ePPIs are the foundation for the cancer immunotherapies, which have 
provided significant benefits for cancer patients. Many other ePPIs in this space are under active investigation. 
(B) SAR-CoV-2 uses its spike protein to co-op the ACE2 receptor for viral entry into host cells and initiate 
viral replication and infection. Strategies for blocking this interaction are being explored to address the 
COVID-19 pandemic.
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systems [12, 13]. Altogether, these biochemical features make most available 
technologies suboptimal and as a result, ePPIs are remarkably underrepresented in 
current databases.
Because of the difficulties with ePPI discovery, many new approaches have been 
developed to specifically identify human ePPIs that play roles in homeostasis and 
disease. While past low-throughput methods and focused studies have provided 
fundamental insights into specific receptors and pathways, the rapid explosion in 
sequencing, mass spectrometry (MS), targeted mutagenesis and high-throughput 
screening techniques has made the exhaustive identification of ePPIs a realistic goal. 
Here, we will address how new techniques deal with unique challenges associated 
with ePPIs and highlight the progress towards to the elucidation of a comprehensive 
network map of all human ePPIs.
2. Methods for detecting ePPIs
From biophysical approaches to in vivo studies, a number of methods have been 
developed or are being improved that have the potential to enable unbiased ePPIs 
discovery. The majority of methods can be categorized into a few broad technological 
concepts: biochemical fractionation, affinity purification, protein-fragment comple-
mentation, proximity labeling, direct protein interaction detection and computa-
tional modeling. As is the case for other disciplines, deciphering the complexities 
of extracellular interactions requires a multipronged approach. Since the different 
approaches provide different types of information, these methodologies are comple-
mentary. Especially as these categories have matured, many new techniques bridge 
the different concepts to balance the various benefits and shortcomings and push for 
increased throughput. The specific method-of-choice will depend on the expertise, 
equipment and overall resources available in each laboratory (Table 1).
2.1 Biochemical fractionation
2.1.1 Concept description
Biochemical fractionation is the splitting of a complex lysate, typically cell or 
















Variable + +++ No ++ +++
Affinity 
Purification
+ + +++ Variable ++ +++
Protein-fragment 
comple-mentation
++ ++ ++ Yes ++ ++
Proximity labeling + +++ ++ No +++ +
Direct interaction 
screens
+++ ++ − +++ + − +++ Yes + +++
Table 1. 
Comparison of approaches for unbiased detecting ePPIs.
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certain biochemical property. The measurable property could be complex cellular 
activities, such as the stimulation of cell migration, or simple ones such as binding 
to a target protein (Figure 2).
2.1.2 Concept pros
Biochemical fractionation does not require any knowledge of the components 
and can be an unbiased technique. It is a versatile concept since any biochemical 
property can be studied, from in vivo tissue level responses to molecular PPIs. Some 
degree of fractionation is easily combined with other techniques to reduce the 
starting complexity and to improve data interpretability.
2.1.3 Concept cons
The results from biochemical fractionations are dependent on the particular 
purification steps used and can be highly variable. Due to the multiple purification 
steps, this approach can also be labor and time intensive. The different purification 
steps can inactivate proteins by inducing misfolding or removing key co-factors. 
This is especially true for ePPIs that involve membrane proteins, which can lose 
activity if extracted from membranes [12, 13].
2.1.4 Specific applications
Biochemical fractionations played a role historically in identifying some of 
the first extracellular signaling proteins like cytokines using activities such as 
macrophage migration or bacteria killing [14]. In the 21st century, this approach 
has identified stable soluble PPIs proteome-wide by fractionating cell lysates 
down to the level of co-eluting protein complexes and identifying them using 
MS [15]. While the specific purification steps used for soluble proteins are 
unlikely to be applicable to ePPIs, alternative centrifugation-based fraction-
ation successfully recovered biochemically active membranes from crude fruit 
fly extracts [16]. Direct application of affinity purification from crude extracts 
without enriching for synaptic membranes did not recover known ePPIs [16]. 
However, using biochemical fractionation to enrich for synaptic components 
was necessary for the identification of key proteins in synapse formation using 
an affinity purification approach (described in the next section) [17].
Figure 2. 
Biochemical fractionation can be used to reduce the complexity of a mixture while maintaining the desired 
activity. While traditionally performed in series, fractionation can also be done in parallel with modern 
purification techniques.
5




Affinity purification involves isolating a target-of-interest in non-denaturing 
conditions to enable co-isolation of any binding partners that are stably attached. 
The most common implementation is immunoprecipitation, where an antibody, 
generally attached to a solid substrate like a bead, plate or column, is used to 
specifically recognize the target-of-interest. Any factors that are not stably bound to 
the protein of interest are washed away by flushing the solid substrate with buffer. 
Proteins that survive the washes are identified (Figure 3).
2.2.2 Concept pros
Affinity purification allows for the direct isolation of a target-of-interest from 
complex mixtures. It is versatile and can be combined with many other approaches.
2.2.3 Concept cons
To isolate the target-of-interest, there needs to be a reagent, like an antibody, 
that will specifically and tightly bind the target. Since such reagents are not always 
readily available, the target may need to be tagged and introduced exogenously, 
which can affect target behavior. Affinity purification for unbiased identification of 
binding partners requires either large tagged libraries or access to MS. Importantly, 
to be identified, binding partners need to survive cell lysis and washes. This has 
limited the applicability of this otherwise widely-utilized approach in the study of 
ePPIs. Cell lysis and target extractions typically require membrane solubilization, 
which can disrupt membrane protein-dependent interactions. In addition, affinity 
purification workflows often miss detection of low affinity interactions, which are 
typical of ePPIs.
2.2.4 Specific applications
The most widely used version of this concept is affinity purification followed 
by binding partner identification using mass spectrometry (AP/MS) (Table 2). MS 
allows for the unbiased identification of interactors in their endogenous form in vir-
tually any cell type or tissue. Traditionally, AP/MS studies were mostly restricted to 
one or a few targets-of-interest. However, recent technological advances, dominated 
Figure 3. 
Affinity purification isolates a protein and any stably interacting protein from a complex solution such as a cell 
or tissue lysate. Shown here is the most common implementation where an antibody is used to isolate the target 
protein, followed by unbiased identification of binding proteins using MS. the antibody is attached to a solid 
substrate to allow for physical manipulations of the target protein.
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by the BioPlex project, have driven the development of a systematic pipeline that 
enables high-throughput AP/MS. Such efforts have already resulted in an interac-
tion network with nearly 120,000 interactions identified for over 14,000 proteins in 
HEK293 cells [18].
A second and more recently developed method is the luminescence-based 
mammalian interactome mapping (LUMIER). In this approach, a library of epit-
ope-tagged (specifically FLAG-tagged) constructs are co-transfected with a target-
of-interest fused to Renilla luciferase. An anti-FLAG antibody is then used to pull 
down the tagged protein and binding is assayed by reading out luciferase activity 
of the immunoprecipitate [19]. Though in principle this approach offers increased 
sensitivity, this technique requires that both the target-of-interest and the library 
are tagged and expressed using artificial constructs. Thus, the applicability of this 
method for unbiased screening greatly depends on the accessibility to large libraries 
of tagged constructs.
While these approaches excel at identifying soluble interactions, ePPIs struggle 
to survive the processing steps and are noticeably underrepresented in both the 
LUMIER and even the much more comprehensive BioPlex dataset. One way to 
address some of the challenges associated to ePPIs is to combine affinity purifica-
tion with cross-linking, turning transient ePPIs into permanent covalent linkages. 
By using cross-linking in combination with mass spectrometry (XL-MS), ePPIs can 
be identified in an unbiased manner. While cross-linking stabilizes weak interac-
tions, XL-MS still has associated challenges like the presence of unproductive cross-
links or combinatorial database search space. To overcome these, newly developed 
cross-linkers used for XL-MS can include affinity tags or MS cleavable moieties 
[20]. However, these increase cross-linker size and the chances of cross-linking 
nearby, non-interacting proteins. Existing cross-linking reagents also primarily 
target reactive amines, limiting the number of protein interactions that can be cap-
tured. Cross-linking protein complexes also tends make them less soluble [21]. This 
is worsened by the fact that ePPIs often involve membrane proteins which already 
present solubility challenges that complicates down-stream processing. Since 
extracellular proteins are often heterogeneously post-translationally modified [22], 
they can be challenging to identify in mass databases for MS experiment. Overall, 
XL-MS represents one of the few techniques that does not have a bias against ePPIs 
over soluble PPIs.
While most cross-linking approaches select for general features of proteins 
like reactive amine groups, alternative strategies have been developed that specifi-
cally target cell-surface receptors using trifunctional cross-linkers. These methods 
typically have one moiety that covalently attaches the cross-linker to the target 
protein-of-interest, a soluble protein that ranges from peptides, to antibodies or 
even complex entities such as viral particles. A second moiety links to glycosylated 
receptor proteins bound to or near the target, and a third moiety enables purifica-
tion. Three molecules and associated workflows have been described: TRICEPS 






Affinity purification techniques covered in this section. These approaches differ primarily in their readout 
method.
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to enable unbiased study of targets of diverse nature in physiologically relevant 
settings such as cells expressing endogenous receptors, thus offering an attractive 
option for ePPI discovery.
2.3 Protein-fragment complementation
2.3.1 Concept description
Protein-fragment complementation refers to methods where a protein with 
reporter activity is split in two and fused to two proteins being tested for binding. 
Since the two halves do not interact with each other on their own, reporter activity 
is only recovered when the halves are fused to interacting proteins. The archetypal 
example of this approach is the yeast two-hybrid system (Y2H) which uses two halves 
of a transcriptional factor that can drive the expression of a report gene (Figure 4).
2.3.2 Concept pros
Protein-fragment complementation is usually performed using living cells 
allowing proteins to be maintained in relatively native conditions. Reporter activity 
often have an amplification step that allows for the sensitive detection of even weak 
interactions [26]. While protein-fragment complementation technically reads out 
proximity, reasonable linker lengths can select for small distances. The interaction 
has to persist long enough for the activity to be reconstituted, reducing false posi-
tives rates when compared to some other proximity-based techniques.
2.3.3 Concept cons
Protein-fragment complementation mandates the tagging of proteins with non-
native sequences for the reporter readout. These tags can be substantial in size and 
affect the behavior of the proteins being tagged. Since the reporter activity depends 
only on the reporter portion being in close proximity, this approach does not 
guarantee a direct interaction. Most systems only test binary interactions by design 
since only the tagged proteins are being assayed.
2.3.4 Specific applications
Y2H has been used extensively to detect PPIs since its conception (Table 3). 
The use of yeast allows for low-cost high-throughput testing of interactions. 
This technique has now been used to detect interactions between 90% of human 
proteins [27]. However, Y2H is not suited for ePPI discovery. The expres-
sion of human proteins in yeast may result in non-native post-translational 
Figure 4. 
General schematic for the protein-fragment complementation approach. Two proteins suspected of interaction 
are each tagged with half of a split reporter protein. The reporter activity is detected only if the split reporter is 
brought together by an interaction between the two tagged proteins.
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Figure 5. 
General schematic of a proximity labeling experiment. A target-of-interest is fused to an enzyme that labels 
nearby proteins with an affinity tag. That tag can then be used to isolate the proteins for identification.
modifications relevant for function, but more importantly, Y2H actively selects 
against ePPIs because the interaction must occur in the nucleus to drive tran-
scriptional readout.
To complement the classic Y2H approaches and overcome the pitfalls related 
to ePPIs, several systems specifically targeting membrane proteins have been 
developed. The membrane yeast two-hybrid (MYTH) [28] and its mammalian 
counterpart, mammalian membrane two-hybrid (MaMTH) [29] require that  
at least one protein being tested is anchored to the plasma membrane. Both of 
these approaches use a split ubiquitin system where one of the two halves is 
fused to a membrane protein and a transcription factor. Tethering the transcrip-
tion factor to the membrane protein keeps it out of the nucleus, preventing 
reporter expression. When the membrane protein interacts with a protein 
containing the second half of ubiquitin, a cleavage event occurs, releasing the 
transcription factor to translocate to the nucleus and initiate reporter expres-
sion. In combination with targeted libraries, this approach has been used for  
the high-throughput detection of interactions between receptor tyrosine kinases 
and phosphatases [30]. However, since these techniques rely on the endogenous 
ubiquitin machinery for cleavage, they mandate that both binding partners  
be expressed in the same cells, limiting applicability of these techniques for 
detection of in-trans interactors.
2.4 Proximity labeling
2.4.1 Concept description
Proximity labeling techniques identify possible PPIs by covalently modifying 
proteins that are in close proximity, typically within a few nanometers. In most 
cases, the label includes an affinity tag like biotin which allows the labeled proteins 
to be purified and identified using MS (Figure 5).
Approach Split reporter system
Yeast two-hybrid Split Gal4 transcription factor driving reporter expression
MYTH/MaMTH Split ubiquitin restricting localization of a transcription factor
Table 3. 
Specific protein-fragment complementation approaches covered in this section. These differ primarily in the 
specifics of the split reporter activity.
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2.4.2 Concept pros
The different proximity proteomics methods have represented some of the 
most significant advances in the field of PPI detection, and in particular membrane 
protein interaction discovery. From the initial development of BioID and its further 
iterations in BioID2 and TurboID, as well as the more recently developed MicroMap, 
these techniques have substantially increased the sensitivity for detection of a range 
of interactions, including weak, transient interactions by translating them into 
permanent covalent linkages. In addition, proximity proteomics approaches are 
generally applicable to complex physiological systems and cellular models of inter-
est, and can bypass over-expression of proteins-of-interest and laborious libraries. 
Furthermore, these approaches also offer the advantage of temporal control, though 
currently this is typically on the tens of minutes time-scale.
2.4.3 Concept cons
While proximity labeling typically does not require any special equipment, the 
unbiased identification of proximal proteins requires access to MS. Since these 
approaches fundamentally readout proximity, the PPI is inferred. Especially if used 
in complex physiological contexts, the possibility of identifying neighboring but 
not directly interacting proteins means that this approach has the greatest challenge 
when it comes to data interpretability. Additionally, the most popular proximity 
proteomics methods, BioID and APEX, require expression of the protein-of-interest 
fused to a bulky tag, followed by over-expression of the fusion protein. Although 
generally applicable to physiologically relevant systems, experimental conditions 
may require optimization to ensure that the overall behavior of the target-of-
interest is not altered by tagging or over-expression.
Currently, these techniques have been applied primarily to detect interactions 
between proteins on the same cells. In many cases, the utility for in-trans interac-
tions remains to be demonstrated.
2.4.4 Specific applications
The different proximity labeling techniques vary based on what enzymes or 
chemistries are used to accomplish the labeling. The field of proximity proteomics 
has been predominantly driven by the development of enzyme-catalyzed proxim-
ity labeling. These typically used a promiscuous biotin ligase (from BioID to the 
much faster TurboID) or a peroxidase (usually APEX or horse radish peroxidase 
(HRP)) to create a highly reactive biotin species that can only diffuse a short 
distance before reacting with nearby proteins or water [31]. When a target protein 
is tagged with one of these enzymes and substrate added, proteins in its vicinity 
are biotinylated, allowing them to be isolated and identified using MS. The par-
ticular techniques differ slightly in their tradeoffs. The peroxidases tend to be more 
broadly reactive and requiring less labeling time. However, they require the addi-
tion of a biotin conjugate and hydrogen peroxide, both of which could be toxic to 
cells. While the biotin ligases do not have this problem, they are on average slower, 
though the more recently engineered TurboID can achieve efficient labeling within 
minutes (Table 4) [31].
This concept has been incorporated into specific techniques for identifying 
ePPIs like selective proteomic proximity labeling assay using tyramine (SPPLAT). 
SPPLAT uses an HRP-conjugated antibody recognizing a cell surface protein. 
High-Throughput Screening for Drug Discovery
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Since the antibody cannot diffuse across the plasma membrane, it specifically tar-
gets ePPIs without any tagging of proteins, and thus enabling studies in unmodi-
fied cellular settings [32]. Another approach is enzyme-mediated activation of 
radical sources (EMARS) which also uses an HRP-conjugated antibody. However, 
EMARS uses a biotin fused to an aryl azide group giving it a large labeling radius 
of 200–300 nm, making it more suitable for characterizing entire microdomains 
rather than ePPIs [33]. Though the use of antibodies has advantages, genetically 
tagging a protein with HRP can allow these types of techniques to be performed 
in the physiological context in an organism. For example, the use of a CD2-HRP 
fusion protein with a membrane-impermeable biotin-phenol allowed the identifi-
cation of cell-type specific neural protein cross talk in the fly brain [34].
The newest addition to the proximity labeling family is MicroMap, which 
uses entirely orthogonal chemistry to the existing techniques. MicroMap uses an 
antibody to detect the target-of-interest, which is then recognized by a secondary 
antibody conjugated to a photocatalyst. The photocatalyst absorbs blue light to 
catalyze the activation of a biotin conjugate molecule in its vicinity. This approach 
uses a more reactive chemical moiety than the biotin ligase or peroxide approaches, 
which allow for an even smaller radius of labeling and thus, is more likely to detect 
direct PPIs. Using MicroMap, the authors proposed a new set of putative binders 
partners for key immune receptors such as PD-L1 [35].
2.5 Direct protein–protein interaction screens
2.5.1 Concept description
Direct interaction screens encompass a wide variety of techniques that have 
several features in common. First, there is a query protein that is the target-of-
interest. Second, the query protein is tested for binding to a library containing 
possible binding partners presented as recombinant proteins or receptors expressed 
on cells. Third, a positive signal in the screen directly reads out an interaction 
between the query and a given binding partner in the library, using detection 
methods that vary depending on the approach. Major distinguishing factors between 
the various direct PPI-screening techniques include: the level of multimerization of 
the target protein (from monomers to oligomeric proteins), the form of the library of 
binding partners being screened (protein-based vs. cell-based formats), as well as the 
degree of purification required (purified protein vs. conditioned media) (Figure 6).
2.5.2 Concept pros
This approach typically allows for the opportunity to control most aspects of the 
screen such as protein concentration and buffer conditions. This approach is also 
Approach Substrate/Cross-linker Moieties
Biotin ligases (BioID, TurboID) Biotin
Peroxidases (APEX, HRP) Different biotin conjugates
SPPLAT Tyramide biotin conjugates
EMARS Aryl azide biotin conjugates
MicroMap Diazirine biotin conjugates
Table 4. 
Specific approaches mentioned in this section for using proximity labeling and cross-linking. These techniques 
differ in the labeling enzymes that they use (for labeling) or the chemistries of the substrate.
11
Unbiased Identification of Extracellular Protein–Protein Interactions for Drug Target…
DOI: http://dx.doi.org/10.5772/intechopen.97310
generally amenable to scale-up. Therefore many modern libraries have high cover-
age of at least specific protein families. The simplicity and the fact that the readout 
reflects direct PPIs also generally leads to straight-forward data analysis.
2.5.3 Concept cons
Many of these approaches use purified proteins and may require the use of 
ectodomains rather than the full-length protein. While the ectodomain is sufficient 
for binding in many instances, this requirement makes it difficult to identify ePPIs 
that use multiple ectodomains or transmembrane domains for binding; a behavior 
documented for the family of seven-transmembrane-domain-containing G protein-
coupled receptors (GPCRs). These approaches also typically require that the target-
of-interest be screened against a library, which needs to be comprehensive for truly 
unbiased identification if ePPIs. The generation and maintenance of a large library, 
either as recombinant proteins or plasmids for expression on cells, can be costly and 
may require access to automation.
2.5.4 Specific applications
While published work tends to take advantage of specific combinations of 
the type of target presentation and the type of library, significant mixing and 
matching is possible due to the similarity in the overall conceptual framework. 
Therefore, we will talk about the major types of target presentation and library 
separately and mention any incompatibilities. Also, since there are a large diver-
sity of library formats, we divided the formats into protein-based libraries and 
cell-based libraries, though the same target presentation strategies can be used 
for both (Table 5).
Figure 6. 
General schematic for direction protein interactions screens. The library of proteins can be directly immobilized 
on a solid substrate or be expressed on cells. Alternative multimerization methods have been developed to 
present the query protein of interest, reviewed in the text.
Target Presentation Protein-based Library Cell-based Library
Dimer (Fc tag) Protein microarray (on slide) cDNA libraries (on slide)
Pentamer (COMP tag) Purified protein (in plate) cDNA libraries (on plate)
Beads-based Multimer 
(variable)
Purified protein (SPR chip) CRISPRa gRNA libraries
Purified protein (Magneto-sensor 
chip)
Knock-down or Knock-out 
libraries
Conditioned media protein (in 
plate)
Table 5. 
Lists of target presentations and protein and cell-based library formats covered in this section.
High-Throughput Screening for Drug Discovery
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2.5.4.1 Target presentation methods
To be able to directly assay interactions, targets-of-interests are typically presented 
as recombinant protein for this type of approach. While secreted proteins are soluble 
and can be directly screened, membrane proteins tend to misfold and aggregate if they 
are extracted from membranes because of their hydrophobic transmembrane domains 
[12, 13]. Since ectodomains are usually the portion of transmembrane proteins avail-
able for direct ePPIs, typically only ectodomains are used for direct ePPI screening.
A number of multimerization approaches that increase query protein avidity 
and therefore facilitate detection of transient interactions have been developed. 
In particular, there are three dominant strategies: dimerization induced by fusing 
ectodomains to the constant Fc region of antibodies [36], pentamerization induced 
by fusing ectodomains to the rat cartilage oligomeric matrix protein (COMP) [37] 
and higher order multimerization using small beads with high protein-binding 
capacity, usually in the form of protein A-coated or streptavidin-coated beads.
While increased multimerization is a major factor for increasing sensitiv-
ity with target presentation, the readout method to measure target binding also 
varies. Using Fc-tagged dimers allows the detection of the target using a variety of 
secondary antibodies or protein A/G that bind to Fc regions with high affinity [36]. 
However, using enzymatic readouts can add a high degree of signal amplification 
that allows for increased sensitivity. Therefore, the approach used to generate the 
largest ePPI networks to date uses pentamerization combined with an enzymatic 
β-lactamase colorimetric assay [37–40]. As for bead-based approaches, the specific 
readout can be magnetic, fluorescent or chemiluminescent depending on the 
specific screening method used [41, 42].
Lastly, some of the recent high-throughput technologies use conditioned media 
enriched for the target-of-interest rather than purified proteins. Using conditioned 
media involves direct capture of secreted protein or protein ectodomains in the 
absence of protein purification, thus minimizing potential inactivation of the 
proteins due to purification steps. The use of conditioned media can also save time 
and resources, helping to make the approaches more accessible to different labora-
tory and more amenable to scaling up [37–40].
2.5.4.2 Protein-based library formats
Different protein-based library formats can allow for different levels of through-
put and information collected about the binding interactions. The most common 
and high-throughput approaches are generally qualitative, detecting whether the 
interaction is present, but not providing quantitative information such as kinetic 
parameters. One example of this type of library is the protein microarray, which for 
ePPIs, contains different purified secreted proteins or ectodomains directly spotted 
on slides. Only small amounts of each protein are used, allowing for the dense tiling 
of thousands of proteins per slide. The compact format allows slides to be covered 
with a small volume of fluorescently-labeled target protein, rinsed and imaged using 
microscopy [43]. While this is a convenient format, the construction of the protein 
microarrays is often costly because it requires all of the proteins to be purified.
Another type of library for qualitative ePPI identification uses plate-based 
screening formats. The use of plates allows for the easy addition of proteins and 
controlled washes without the need for specialized microfluidics. While purified 
proteins can be used, plate-based formats allow for the direct capture of secreted 
tagged proteins from conditioned media. Capture of biotinylated proteins using 
streptavidin-coated plates [37] or Fc-tagged proteins using Protein A-coated plates 
[38–40] followed by washing allows for the effective purification of library proteins 
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in wells while adding sensitivity by multimerizing (in the case of multivalent 
binding of streptavidin to biotin) or capturing already multimerized proteins. This 
approach also allows the use of enzymatic liquid phase readouts: β-lactamase-based 
colorimetric assays or luciferase-based luminescence assays which provides an 
additional degree of signal amplification. The plate-based approach also gives one 
value per well, allowing for simple data analysis and the greatest interpretability.
While the plate-based approach is generally the most scalable options, other 
techniques trade some scale for quantitative information on ePPIs. In particular, 
microfluidics, automation and miniaturization has pushed label-free biophysical 
techniques to be more high-throughput. For example, the combination of micro-
fluidics and either surface plasmon resonance (SPR) or magneto-nanosensors has 
increase the scale enough to study all combinatorial interactions between a small 
number of proteins, making it especially adept at addressing complex cross-talk 
between small interaction networks [44, 45]. While SPR is the gold standard 
technique for biophysical characterization of protein interactions and calculation of 
kinetic parameters, the magneto-nanosensor platform provides higher degrees of 
sensitivity, and therefore, requiring less material to detect weak ePPIs. However, it 
requires the use of magnetic nanoparticles conjugated to the target-of-interest. The 
nanoparticles are are flowed over patches of library proteins printed on magneto-
nanosensors that detect a change in electrical resistance if a nanoparticle is nearby 
[45]. Another technique that also provides similar information is biolayer inter-
ferometry (BLI) which translates protein binding into a light interference signal. 
While typically less sensitive than SPR and the magneto-nanosensor platform, BLI 
excels in its ease-of-use. BLI uses small, disposable sensors that can be coupled to 
targets-of-interest, typically through the capture of tag like Fc-tags or biotin. The 
sensors are then simply dipped into wells containing the potential binding partners 
in solution. With advances in automated and miniaturized BLI setups, it can be used 
to screen for interactions in high-throughput, provided that libraries of recombinant 
proteins are available. This technology helped identify the PVR-TIGIT interaction 
[46] which is mechanistic foundations of the anti-TIGIT immunotherapy [47].
2.5.4.3 Cell-based library formats
Even though protein-based libraries have many advantages such as stor-
ability and easy data interpretation, they can often fail to detect ePPIs because 
of biochemical challenges associated with membrane proteins. Many membrane 
proteins lose activity when truncated into soluble ectodomains or extracted from 
membranes. In addition, the complex cellular membrane environment can pro-
vide important protein and non-protein co-factors, orient and cluster membrane 
proteins and assist in high-order complex formation. Therefore, hard to purify 
receptors are often screened against cDNA libraries expressing membrane proteins 
directly on cells. This is especially true for important drug targets like GPCRs and 
ion channels [48] which have multiple transmembrane domains and typically small 
extracellular regions.
To screen for interactions using cell-based formats, libraries are used to either 
induce loss-of-function (lack of binding) or gain-of-function (increased bind-
ing). In the loss-of-function approach, possible binders of a target-of-interest are 
knocked down or knocked out either randomly using chemical mutagens or trans-
posons like gene trap [49] or in a targeted manner with siRNA, zinc-finger nuclease, 
transcription activator-like effector nuclease (TALEN) or clustered regularly 
interspaced short palindromic repeat (CRISPR) libraries [50]. When the target-of-
interest is incubated with the cells, the target should not interact if the interaction 
partner has been depleted. However, it may be difficult to identify cells that bind 
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the target-of-interest. In addition, the interaction must to be simple enough that 
knocking down one interaction partner causes a detectable decrease in binding.
To avoid these limitations, an alternative approach is to overexpress receptors that 
may participate in ePPIs. This is most commonly done using cDNA libraries. The DNA 
libraries are spotted on slides [51] or plated into wells [52], with each spot or well con-
taining a vector encoding for a different protein. Cells are then added and transfected 
to induce them to overexpress the protein and display them on the plasma membrane. 
If the cells are expressing the receptor for the target-of-interest, this can be detected by 
increased target binding to the surface of the cell. This approach has been successfully 
utilized to deorphanize secreted factors [53], interactions between immune receptors 
[54], or identify glycan-dependent recognition of specific ligands [55]. However, 
the generation and management of cDNA libraries that have significant coverage 
of membrane proteins can be expensive and not accessible to many investigators. In 
addition, selective expression of the myriad of possible receptors isoforms that may 
participate in ligand binding makes truly comprehensive cDNA libraries infeasible. 
One way to address isoform-specific expression while facilitating library management 
is to use CRISPR activation (CRISPRa). In this implementation, CRISPR-Cas9 fused 
to transcriptional activation domains is coupled to guide RNAs selectively targeting 
cell-surface genes to overexpress receptor proteins. A high coverage CRISPRa guide 




Computational models cover a large range of concepts that attempt to predict 
PPIs based on existing knowledge of the biochemistry of protein binding and 
features of proteins, such as the sequence, conserved residues or structural features.
2.6.2 Concept pros
Computational models can offer relatively less resource-consuming and faster 
alternatives to experimental research. They allow for the theoretical exploration of 
PPIs without regard for experimental challenges related to expression of proteins 
or development of workflows or platforms. Modern machine learning approaches 
may also identify unintuitive features that are the most predictive for interactions 
such as unappreciated modifications. They can also draw from larger pools of 
information, taking into account protein expression patterns, genetic variations and 
dysregulation in disease.
2.6.3 Concept cons
Computational modeling approaches to identify PPIs, not to mention ePPIs, 
are still in their infancy, with overall low rates of accuracy. Many are based on our 
existing knowledge of experimentally determined interactions, which may have 
biases and is incomplete. Approaches that attempt to model binding interfaces are 
too computationally expensive to be high-throughput even when experimentally 
determined protein structures exist [57].
2.6.4 Specific applications
Since computational approaches remain immature for human ePPIs, we 
will mostly highlight the different computational resources and a few different 
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approaches rather than try to describe a list of the major algorithms. However, this 
is a rapidly developing area mirroring the explosion in available experimental datas-
ets, including data from all of the approaches mentioned so far as well as expression 
data for cell types, tissue and now single cells identifying which proteins are at the 
same places at the same times (Table 6) [58, 59].
The increased availability of comprehensive databases for PPIs, and more 
recently ePPIs, have fueled diverse computational approaches. Efforts like STRING 
[60] and BioGRID [61] which collects and curates public data on PPIs, are often 
drawn on for model development and are also important resources for individual 
researchers looking for the next interaction to drug. There are also many databases 
that document the progress of specific approaches like BioPlex which contains 
thousands of human interactions identified by AP/MS [18] as well as the Research 
Collaboratory for Structural Bioinformatics Protein Data Bank which captures 
many structures showing the molecular details of PPIs [62]. However, even here 
ePPIs have posed a challenge because we do not have a definitive list of all proteins 
that reach the cell surface in various tissues and cell types, though ongoing efforts 
are trying to experimentally answer that question [59, 63–65]. Recently, the human 
surfaceome was estimated using a machine learning model to predict the cell 
surface localization of almost 3000 proteins [66].
Modeling approaches that actually attempt to predict ePPIs range in terms of the 
types of information they try to account for. While not yet applied to human ePPIs, the 
use of residue-residue coevolution in combination with structure modeling successfully 
predicted many ePPIs in bacteria [67]. Another approach, PICTree, focused on the 
structurally related immunoglobulin superfamily (IgSF) of proteins, using knowledge 
of family members with known binding partners and sequence conservation to 
predict new interactions using [68]. Lastly, some approaches use broad information 
sets about a gold standard set of interactions. For example, FpClass trains their model 
on everything amino acid makeup to post-translational modifications to expression 
patterns [69]. However, this still resulted in an estimated false discovery rate of 60%, 
which shows that while modeling can assist in hypothesis generation, there is more 
work to be done before modeling would take the place of experimental approaches.
3. Summary
Extracellular protein–protein interactions are an important set of possible drug 
targets. They are commonly dysregulated in disease and can be targeted to alter 
disease phenotypes. Practically, ePPIs are exposed on the cell surface, making them 
easier to access using therapeutic approaches. However, because of challenges asso-
ciated with ePPI biochemistry, most membrane proteins and secreted factors do 
Approach Details
STRING Database of PPIs predictions based on public data
BioGRID Database of curated public PPI data
BioPlex Database of human PPI identified by AP/MS
Coevolution PPI prediction based on coevolution of residues
PICTree Functional clustering using hidden Markov models
FpClass PPI prediction using machine learning
Table 6. 
List of computational resources and approaches covered in this section.
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not have identified interactions. Elucidating the extracellular interaction networks 
in humans as well as their dysregulation during disease will be key to understand 
basic biology and fuel new or improved drug development efforts. To tackle this 
daunting challenge, researchers have applied genetic, chemical, biochemical and 
computational approaches to come up with an ever-growing list of ePPIs. Here we 
have reviewed the progress made in the last decade in technologies suitable for the 
study of ePPIs. In particular, we discuss those approaches that can be applied to the 
high throughput screening of ePPIs in an unbiased fashion.
4. Future perspectives
As costs are continually falling on readouts like sequencing and mass spectrometry, 
and as throughput increases with better automation and computational analysis, the 
future looks bright in the field of ePPI identification. More and more techniques will 
cross over the categories that we have laid out, finding middle points that balance the 
various tradeoffs of ease, interpretability, and physiological relevance.
One exciting development that 2020 brought was the release of two large-
scale efforts using ePPI-optimized pentamer-based direct interaction screening 
approaches. These efforts each systematically tested hundreds of thousands of 
pairwise interactions, focusing on the IgSF of single-pass transmembrane proteins, 
the largest family of secreted and membrane-expressed proteins in the human 
genome [39, 40]. These large interaction networks identified hundreds of new 
interactions and present the most extensive ePPI network maps to date.
Once the interactions are found, we need to be able to manipulate them in 
humans to cure diseases. While not the topic of this chapter, several exciting 
developments on the drug development front holds much promise for targeting 
ePPIs. New highly selective inhibitors that recognize the transmembrane domains 
of protein, such as the isoform-selective inhibitor of the Nav1.7 channel, can 
provide novel classes of chemical inhibitors of transmembrane proteins to disrupt 
ePPIs [70]. While cytokines often offer desirable ways to manipulate many immune 
functions, they are often like playing with fire because of their many disparate 
effects. However, with improvements in protein design, completely artificial 
cytokine mimics can now be made which can be highly selective for activities that 
are desired and counter selected for activities that are not [71].
One major challenge that lies ahead is to not to just identify ePPIs but to identify 
disease relevant human ePPIs. Along these lines, a recently published map of the 
IgSF highlighted the power of big data integration, showing that the combination 
of clinical data with a focus on the protein pair participating in ePPIs gave greater 
predictive value than each of the proteins alone [39], suggesting that targeting 
specific ePPIs may be more beneficial than targeting an individual protein. Another 
challenge is the reliance on animal models. Plasma membrane and secreted factors 
are some of the least conserved of all proteins [72], having to evolve to adapt to our 
unique physiology. As more complex human ePPI networks are discovered, it will be a 
challenge to understand their impacts at the organismal level. Whether it be organoid 
systems or better functional assays, with the rapid growth in ePPI identification 
technologies, soon we’ll have to find high-throughput ways to ask, what do they do?
5. Executive summary
• Extracellular protein–protein interactions (ePPIs) make for good drug 
targets because they control many biological processes and are accessible to 
therapeutic agents.
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• An estimated third of all human genes encode for proteins that may be 
involved in ePPIs, necessitating high-throughput approaches for unbiased 
discovery.
• General PPI detection techniques often fail to overcome challenges posed by 
extracellular proteins, leading to the development of ePPI-specific approaches.
• EPPI-specific technologies address some of these challenges directly, such 
as using multimerization to strengthen characteristically weak interactions 
or assaying interactions on cells to avoid difficult membrane protein 
purifications.
• Techniques typically balance several tradeoffs, mainly: control and 
interpretability versus physiological relevance, rates of false positive versus 
false negative results, and scale and coverage versus time and expense.
• Specific techniques fall into broad categories: biochemical fractionation, 
affinity purification, protein-fragment complementation, proximity labeling, 
direct interaction and computational modeling that can be synergistic for ePPI 
discovery.
• New ePPIs are still being discovered with the aid of new techniques, suggesting 
that many remain to be found. The methodologies discussed in this chapter 
should set the bases for identification and characterization of novel ePPIs in 
humans and other model organisms.
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